Published in J Natl Cancer Inst on December 01, 1999
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol (2015) 1.84
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
TPMT in the treatment of Crohn's disease with azathioprine. Gut (2002) 1.79
The potential and limitations of personalised medicine in primary care. Br J Gen Pract (2003) 1.75
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2011) 1.53
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol (2012) 1.52
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia (2008) 1.33
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Disparities in cancer outcomes: lessons learned from children with cancer. Pediatr Blood Cancer (2011) 1.15
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15
Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol (2013) 1.14
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood (2006) 1.10
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09
Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia. Arch Dis Child (2004) 1.08
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2008) 1.05
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2012) 1.03
Cancer pharmacogenetics. Br J Cancer (2004) 1.01
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 0.99
Negative energy balance and hepatic gene expression patterns in high-yielding dairy cows during the early postpartum period: a global approach. Physiol Genomics (2010) 0.98
Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut (2003) 0.98
Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am (2015) 0.97
Implementation of TPMT testing. Br J Clin Pharmacol (2014) 0.96
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol (2014) 0.95
Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol (2001) 0.94
Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol (2008) 0.94
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet (2016) 0.93
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol (2009) 0.92
Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin Drug Metab Toxicol (2008) 0.92
Functional analysis of human microsomal epoxide hydrolase genetic variants. Chem Biol Interact (2004) 0.91
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Cancer pharmacogenomics. Clin Pharmacol Ther (2011) 0.89
Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88
NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J (2015) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol (2014) 0.86
Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol (2004) 0.85
Genetic variability of pain perception and treatment--clinical pharmacological implications. Eur J Clin Pharmacol (2011) 0.84
Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer (2014) 0.84
Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer (2011) 0.84
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol (2014) 0.83
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist (2011) 0.83
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics (2010) 0.83
Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther (2016) 0.82
Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy. Turk J Haematol (2014) 0.82
Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia. Clin Proteomics (2011) 0.82
Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol (2007) 0.81
Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. Front Genet (2014) 0.81
Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol (2015) 0.81
ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics. Mutat Res (2013) 0.80
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population. Eur J Clin Pharmacol (2008) 0.80
Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst (1999) 0.80
Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J (2014) 0.80
Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur J Clin Pharmacol (2008) 0.79
Validation of new allele-specific real-time PCR system for thiopurine methyltransferase genotyping in Korean population. Biomed Res Int (2013) 0.79
Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia. Eur J Clin Pharmacol (2013) 0.78
The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core. J Struct Biol (2013) 0.78
TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer (2009) 0.78
Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist (2011) 0.78
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther (2016) 0.78
Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population. Libyan J Med (2015) 0.78
Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS One (2011) 0.78
The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics (2017) 0.78
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol (2016) 0.77
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clin Pharmacokinet (2016) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med (2010) 0.77
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics (2014) 0.76
Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics (2016) 0.75
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenomics Pers Med (2016) 0.75
Clinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study. Indian J Med Paediatr Oncol (2016) 0.75
Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952. Leuk Res Rep (2015) 0.75
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med (2017) 0.75
Meta-analysis of the impact of thioprine S-methyltransferase polymorphisms on the tolerable 6-mercaptopurine dose considering initial dose and ethnic difference. Onco Targets Ther (2016) 0.75
Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases. EPMA J (2011) 0.75
Correlation of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in Han Chinese patients treated with azathioprine 25 to 100 mg: A 1-year, single-center, prospective study. Curr Ther Res Clin Exp (2006) 0.75
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci (2016) 0.75
Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity. Br J Clin Pharmacol (2015) 0.75
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood (1995) 2.89
Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet (1993) 2.85
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science (1998) 2.31
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys (1995) 2.01
Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med (1993) 1.99
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol (2000) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood (1991) 1.74
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Childhood adrenocortical tumors. J Clin Endocrinol Metab (1997) 1.64
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Review of small bowel obstruction at Milwaukee County General Hospital. Am J Surg (1966) 1.56
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol (1998) 1.55
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst (1996) 1.54
Bypass grafting to distal arteries for limb salvage. Surg Gynecol Obstet (1972) 1.54
Determination of viability of ischemic intestine by Doppler ultrasound. Surgery (1978) 1.54
Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian Group for Treatment of Childhood Adrenocortical Tumors. Am J Clin Pathol (1994) 1.53
Identification of a tumor necrosis factor-responsive element in the tumor necrosis factor alpha gene. J Biol Chem (1991) 1.52